Ciltacabtagene autoleucel is a type of CAR T-cell therapy that is composed of genetically modified T-cells from the patient, which are directed against the B-cell maturation antigen.
It was approved for the treatment of adult patients with relapsed or refractory multiple myeloma after the failure of prior lines of therapy.